Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 4, 2016, Pages 391-399

  Brito Zerón, Pilar ^a,b   Bosch, Xavier ^b   Pérez de Lis, Marta ^c   Pérez Álvarez, Roberto ^c   Fraile, Guadalupe ^d   Gheitasi, Hoda ^a   Retamozo, Soledad ^a   Bové, Albert ^a   Monclús, Ester ^b   Escoda, Ona ^b   Moreno, Asunción ^b   López Guillermo, Armando ^b   Khamashta, Munther A ^e   Ramos Casals, Manuel ^a,b   Ayala, M M ^f   Barragan Gonzalez M J ^g   Bosch, X ^h   Bove A ^h   Brito Zeron P ^h   Calvo, G ⁱ   Callejas, J L ⁱ   Caminal Montero, L ^j   Camps, M T ^f   Canora Lebrato, J ^k   Castillo Palma, M J ^l   Colodro, A ^e   Cuadrado, M J ^b   de Ramon E ^f   Diaz Lagares C ^m   Egurbide, M V ⁿ   Galiana, D ^k   Garcia Hernandez F J ^o   Gil, A ^p   Gomez de la Torre R ^q   Gonzalez Leon R ^l   Hidalgo, C ^r   Jimenez Alonso J ^r   Khamashta, M A ^b   Martinez Berriotxoa A ⁿ   Medrano, F ^s   Mico M L ^t   Munoz S ^h   Ocana C ^o   Oristrell, J ^u   Ortego Centeno, N ⁱ   Pallares L ^c   Perales Fraile, I ^k   Perez de Lis M ^u   Perez Alvarez, R ^u   Rascon J ^c   Retamozo, S ^h   Rios Blanco J J ^o   Robles, A ^o   Ruiz Irastorza, G ⁿ   Saez, L ^v   Salvador, G ^w   Sanchez Roman J ^o   Selva O'Callaghan, A ^x   Simeon C P ^x   Siso A ^y   more..

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g Hospital Valledel Nalón   (Spain)

^h HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁱ University Hospital Central of Asturias   (Spain)

^j HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l Hospital Materno Infantil   (Spain)

^m HOSPITAL DE CRUCES   (Spain)

ⁿ HOSPITAL DE CABUEÑES   (Spain)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p HOSPITAL SAN AGUSTÍN   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^r HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^s University Hospital La Fe   (Spain)

^t HOSPITAL DE SABADELL   (Spain)

^u HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^v HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^w Hospital de Sagunt   (Spain)

^x HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^y CAPSE GESCLINIC   (Spain)

more..

Author keywords

Anti TNF; Biological therapy; Hemophagocytic syndrome; Mortality; Tuberculosis

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; CANAKINUMAB; CREATININE; ETANERCEPT; FERRITIN; INFLIXIMAB; LACTATE DEHYDROGENASE; RITUXIMAB; TOCILIZUMAB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BRUCELLOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEMOPHAGOCYTIC SYNDROME; HISTOPLASMOSIS; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEISHMANIASIS; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; LUNG DISEASE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATIC DISEASE; SKIN DISEASE; SPLENOMEGALY; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; AUTOIMMUNE DISEASES; COMPLICATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; RHEUMATIC DISEASES; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFECTION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; RHEUMATIC DISEASES; RISK FACTORS; YOUNG ADULT;

EID: 84959454144     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.07.004     Document Type: Article

References (53)

1. Ramos-Casals M., Brito-Zerón P., López-Guillermo A., Khamashta M.A., Bosch X. Adult haemophagocytic syndrome. Lancet 2014, 383:1503-1516.
2. Emmenegger U., Schaer D.J., Larroche C., Neftel K.A. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 2005, 135:299-314.
3. Henter J.I., Elinder G., Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 1991, 18:29-33.
4. Henter J.I., Aricò M., Egeler R.M., Elinder G., Favara B.E., Filipovich A.H., et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 1997, 28:342-347.
5. Perez-Alvarez R., Pérez-de-Lis M., Ramos-Casals M. BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013, 25:56-64.
6. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007, 86:242-251.
7. Ramos-Casals M., Perez-Alvarez R., Perez-de-Lis M., Xaubet A., Bosch X. BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011, 124:386-394.
8. Ramos-Casals M., Roberto-Perez-Alvarez, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
9. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soto M.J. BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine 2008, 87:345-364.
10. Henter J.I., Tondini C., Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol 2004, 50:157-174.
11. Mehta B.M., Hashkes P.J., Avery R., Deal C.L. A 21-year-old man with Still[U+05F3]s disease with fever, rash, and pancytopenia. Arthritis Care Res (Hoboken) 2010, 62:575-579.
12. Moltó A., Mateo L., Lloveras N., Olivé A., Minguez S. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with dalimumab. Joint Bone Spine 2010, 77:271-273.
13. Agarwal S., Moodley J., Ajani Goel G., Theil K.S., Mahmood S.S., Lang R.S. A rare trigger for macrophage activation syndrome. Rheumatol Int 2011, 31:405-407.
14. Bauer M.P., van Burgel N.D., Marijt W.A., van Dissel J.T., von dem Borne P.A. Fever, shock, and pancytopenia in a patient treated with alemtuzumab. Clin Infect Dis 2009, 49:1616-1617.
15. van Koeveringe M.P., Brouwer R.E. Histoplasma capsulatum reactivation with haemophagocytic syndrome in a patient with chronic lymphocytic leukaemia. Neth J Med 2010, 68:418-421.
16. Machaczka M., Vaktnäs J., Chiang S.C., Bryceson Y.T. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010, 7:10.
17. Banse C., Vittecoq O., Benhamou Y., Gauthier-Prieur M., Lequerré T., Lévesque H. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still[U+05F3]s disease. Joint Bone Spine 2013, 80:653-655.
18. Stern A., Riley R., Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still[U+05F3]s disease after initiation of etanercept therapy. J Clin Rheumatol 2001, 7:252-256.
19. Sandhu C., Chesney A., Piliotis E., Buckstein R., Koren S. Macrophage activation syndrome after etanercept treatment. J Rheumatol 2007, 34:241-242.
20. Gianella S., Schaer D.J., Schwarz U., Kurrer M., Heppner F.L., Fehr J., et al. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still[U+05F3]s disease and concurrent macrophage activation syndrome. Am J Hematol 2008, 83:424-427.
21. Sterba G., Sterba Y., Stempel C., Blank J., Azor E., Gomez L. Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis. Isr Med Assoc J 2010, 12:443-445.
22. Kaneko K., Kaburaki M., Muraoka S., Tanaka N., Yamamoto T., Kusunoki Y., et al. Exacerbation of adult-onset Still[U+05F3]s disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis 2010, 13:e67-e69.
23. Araki D., Fujii H., Matsumura M., Yamagishi M., Yachie A., Kawano M. Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med 2011, 50:1843-1848.
24. Aouba A., De Bandt M., Aslangul E., Atkhen N., Patri B. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) 2003, 42:800-802.
25. Chauveau E., Terrier F., Casassus-Buihle D., Moncoucy X., Oddes B. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn[U+05F3]s disease. Presse Med 2005, 34:583-584.
26. Kohara M.M., Blum R.N. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2006, 42:733-734.
27. Francolla K.A., Altman A., Sylvester F.A. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J Pediatr Gastroenterol Nutr 2008, 47:193-195.
28. Troncoso Mariño A., Campelo Sánchez E., Martínez López de Castro N., Inaraja Bobo M.T. Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab. Pharm World Sci 2010, 32:117-119.
29. Numakura T., Matsuura Y., Takiguchi H., Hara Y., Ameku K., Takashi H. Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab. Nihon Kokyuki Gakkai Zasshi 2010, 48:449-453.
30. Presti M.A., Costantino G., Della Torre A., Belvedere A., Cascio A., Fries W. Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn[U+05F3]s colitis: harmful cure?. Inflamm Bowel Dis 2011, 17:E145-E146.
31. Oda Y., Urushidani Y., Ooi S., Endoh A., Nakamura R., Adachi K., et al. Hemophagocytic lymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab. Intern Med 2012, 51:655-657.
32. André V., Liddell C., Guimard T., Tanguy G., Cormier G. Macrophage activation syndrome revealing disseminated tuberculosis in a patient on infliximab. Joint Bone Spine 2013, 80:109-110.
33. Johnston A., Salles G., Espinouse D., Felman P., André P., Berger F., et al. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy. Clin Lymphoma Myeloma 2008, 8:356-358.
34. Meneses A., Epaulard O., Maurin M., Gressin R., Pavese P., Brion J.P., et al. Brucella bacteremia reactivation 70 years after the primary infection. Med Mal Infect 2010, 40:238-240.
35. Kamiya K., Kurasawa K., Arai S., Maezawa R., Hanaoka R., Kumano K., et al. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol 2010, 20:81-85.
36. Tiong I.S., Lau M.B., Toumoua S., Chiruka S. A case of hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia after treatment with fludarabine, cyclophosphamide, and rituximab chemotherapy, with autopsy findings. Case Rep Hematol 2012, 326053.
37. De Bandt M., Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still[U+05F3]s disease. Ann Rheum Dis 2009, 68:153-154.
38. Kobayashi M., Takahashi Y., Yamashita H., Kaneko H., Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still[U+05F3]s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011, 21:92-96.
39. Shimizu M., Nakagishi Y., Kasai K., Yamasaki Y., Miyoshi M., Takei S., et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012, 58:287-294.
40. Henter J.I., Aricò M., Egeler R.M., Elinder G., Favara B.E., Filipovich A.H., et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 1997, 28:342-347.
41. Henter J.I., Horne A., Aricó M., Egeler R.M., Filipovich A.H., Imashuku S., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48:124-131.
42. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
43. Bingham S.J., Buch M.H., Kerr M.A., Emery P., Valadäo Barcelos A.T. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 2004, 50:4072-4073.
44. Ramos-Casals M., Brito-Zerón P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
45. Ramos-Casals M., Brito-Zerón P., Cuadrado M.J., Khamashta M.A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 2008, 10:442-448.
46. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
47. Haraoui B., Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006, 18:96-100.
48. Pillet S., Pozzetto B., Jarlot C., Paul S., Roblin X. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis 2012, 44:541-548.
49. Ali T., Yun L., Shapiro D., Madhoun M.F., Bronze M. Viral infections in patients with inflammatory bowel disease on immunosuppressants. Am J Med Sci 2012, 343:227-232.
50. Fries W., Cottone M., Cascio A. Systematic review: macrophage activation syndrome in inflammatory bowel disease. Aliment Pharmacol Ther 2013, 37:1033-1045.
51. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, CD008794.
52. Jain A., Singh J.A. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 2013, 5:265-299.
53. Brastianos P.K., Swanson J.W., Torbenson M., Sperati J., Karakousis P.C. Tuberculosis-associated hemophagocytic syndrome. Lancet Infect Dis 2006, 6:447-454.